Bob Ingram (HBM Healthcare Investments)

Black Di­a­mond brings in ex-GSK CEO Bob In­gram to chart new path in pre­ci­sion on­col­o­gy

Black Di­a­mond Ther­a­peu­tics start­ed the year with a more than $200 mil­lion vault on­to Nas­daq and a clin­ic-bound al­losteric ther­a­py — and now, the young biotech has Glax­o­SmithK­line vet Bob In­gram to help pave its way.

In­gram is set to take the reins from Black Di­a­mond’s found­ing chair­man Brad Bol­zon, the com­pa­ny an­nounced on Tues­day. The Mass­a­chu­setts-based biotech was the first to launch out of Ver­sant’s Ridge­line dis­cov­ery en­gine in 2018, co-found­ed by David Ep­stein and Eliz­a­beth Buck, for­mer de­vel­op­ers of the can­cer drug Tarce­va. Bol­zon will re­main on the board.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.